HER2-zero triple-negative breast cancer (TNBC) is a recently refined subgroup of TNBC in which the tumor shows no detectable HER2 protein at all on standard testing. Until a few years ago, no one made this distinction because all HER2-negative tumors were treated the same way. That changed when newer drugs, especially antibody-drug conjugates, proved they could target tumors with even tiny amounts of HER2 protein. The split between “HER2-zero” and “HER2-low” has reshaped how oncologists think about TNBC, and patients whose tumors score as truly zero face a narrower set of targeted options than those with low-level HER2 expression.
What Makes a Tumor HER2-Zero
Triple-negative breast cancer is defined by what it lacks: the tumor cells test negative for estrogen receptors, progesterone receptors, and HER2 protein.1PubMed Central. Understanding and treating triple-negative breast cancer Within that broader category, HER2-negative tumors used to be lumped together regardless of exactly how much (or how little) HER2 showed up on the pathologist’s slide. The standard test, called immunohistochemistry, scores HER2 expression on a scale from 0 to 3+. Scores of 0 and 1+ were both labeled “HER2-negative” and treated identically.
HER2-zero refers specifically to a score of 0 on that scale, meaning the pathologist sees no staining or only faint, incomplete staining in 10% or fewer of the tumor cells. HER2-low captures scores of 1+ or 2+ (when a follow-up amplification test is negative). The reason this distinction suddenly matters is that HER2-low tumors make up roughly half of all HER2-negative breast cancers, and they now qualify for drugs that were previously reserved for strongly HER2-positive disease.2PubMed Central. Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
Why the Distinction Became Clinically Important
The catalyst was trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that latches onto HER2 protein on the tumor surface and delivers a potent chemotherapy payload directly into the cell. In trials, T-DXd showed meaningful responses even in tumors with very low HER2 expression. This created a practical question: if your tumor registers as HER2-zero, can you still benefit from these newer HER2-directed drugs? Early data from the DAISY trial suggested some activity even in HER2-zero patients, with an objective response rate of about 30% and median progression-free survival around four months in that cohort, compared to roughly 38% and about seven months in the HER2-low group.3PubMed Central. Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review Those HER2-zero responses were unexpected and hinted that some tumors scored as zero might still harbor trace amounts of HER2 the standard test misses.
Still, the gap between HER2-low and HER2-zero matters. In early-stage breast cancer, patients with HER2-low tumors have shown better disease-free and overall survival compared to those with HER2-zero disease, and this held true regardless of whether the tumor was hormone receptor-positive or hormone receptor-negative. Among hormone receptor-negative patients (which includes most TNBC), HER2-low was linked to better outcomes for both disease-free and overall survival.4Cancer Treatment Reviews. HER2-low breast cancer: Clinicopathological characteristics, prognostic significance and future directions Whether this reflects underlying biology or is partly a consequence of HER2-low patients gaining access to additional targeted therapies is still being sorted out.
The Testing Problem
Here is where the science gets uncomfortably messy. The entire HER2-zero versus HER2-low distinction rests on a pathology test that was originally designed to do something much simpler: sort tumors into “HER2-positive” (eligible for trastuzumab) or “HER2-negative” (not eligible). The test was never built to draw fine lines at the very bottom of the scoring scale. International expert panels have raised concerns about low agreement between pathologists when it comes to distinguishing a score of 0 from 1+.5Modern Pathology. International Expert Consensus Recommendations for HER2 Reporting and Testing in Breast Cancer: Focus on HER2-Low and Ultralow Categories Two pathologists looking at the same slide may disagree on whether a tumor is HER2-zero or HER2-low, and that disagreement can determine which treatments are on the table.
This variability is not a minor academic concern. If a tumor is called HER2-zero on one reading and HER2-low on another, it could mean the difference between qualifying for T-DXd or not. Some institutions have started requesting repeat testing or second opinions precisely because the stakes of this borderline call have risen so steeply. Researchers are also exploring newer, more sensitive methods to detect HER2 at ultralow levels, though none have been standardized for routine clinical use yet.
How HER2-Zero TNBC Is Treated Today
Because HER2-zero TNBC lacks the three most common drug targets in breast cancer, treatment relies heavily on chemotherapy and, increasingly, immunotherapy. For early-stage disease, the standard approach involves neoadjuvant chemotherapy (given before surgery) to shrink the tumor. Adding carboplatin to anthracycline and taxane regimens has improved complete pathologic response rates, meaning the tumor is entirely eliminated by the time of surgery.6PubMed Central. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis
Achieving that complete response matters enormously for long-term outcomes. In one study, patients who had a complete pathologic response after neoadjuvant chemotherapy had a three-year relapse-free survival of 90% and overall survival of 94%, compared to 66% and 79% in patients with residual disease.7PubMed Central. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel This makes the quality of the surgical pathology report one of the strongest predictors of how a patient will do.
Pembrolizumab, a checkpoint inhibitor, has become part of the standard neoadjuvant regimen for many TNBC patients. It is given alongside chemotherapy before surgery and continued as a single agent afterward. Real-world data from Japanese institutions have reported pathologic complete response rates around 57% with this combination.8PubMed. Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study The addition of immunotherapy represents one of the biggest treatment advances for TNBC in the past decade, and it applies to HER2-zero tumors just as much as HER2-low ones, since the immune checkpoint mechanism does not depend on HER2 expression.
When Disease Comes Back After Surgery
If residual disease is found at surgery, oncologists escalate adjuvant (post-surgery) treatment. Capecitabine, an oral chemotherapy, and olaparib, a PARP inhibitor for patients carrying BRCA1 or BRCA2 mutations, have both demonstrated disease-free and overall survival benefits in this setting.9PubMed. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment PARP inhibitors exploit a vulnerability in BRCA-mutant cancer cells: those cells already have a broken DNA-repair pathway, and blocking PARP takes away their backup repair mechanism, causing the cells to accumulate fatal DNA damage.10Expert Review of Anticancer Therapy. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
For metastatic HER2-zero TNBC, sacituzumab govitecan has emerged as a major option. This antibody-drug conjugate targets Trop-2, a protein found on the surface of most TNBC cells regardless of HER2 status. In a randomized trial, it nearly doubled overall survival compared to standard single-agent chemotherapy (about twelve months versus roughly seven months) and tripled the time before the cancer worsened.11PubMed. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Because sacituzumab govitecan targets Trop-2 rather than HER2, it works for HER2-zero patients, making it one of the first targeted therapies to reach this otherwise hard-to-treat group.
Liquid Biopsies and Monitoring Recurrence
One of the challenges with TNBC, including HER2-zero disease, is that relapses tend to happen early and aggressively. Researchers have been studying circulating tumor DNA, fragments of tumor genetic material shed into the bloodstream, as a way to detect residual or returning cancer before it shows up on imaging. A systematic review and meta-analysis found that patients who tested positive for circulating tumor DNA after completing neoadjuvant therapy had roughly four times the risk of recurrence and more than three times the risk of death compared to those who tested negative.12PubMed Central. Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis
Individual studies paint a similar picture. In one cohort, three-year event-free survival was 48% in patients with detectable circulating tumor DNA versus 82% in those without it. Three-year overall survival showed a comparable gap: 50% versus 86%.13npj Breast Cancer. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease This kind of blood-based monitoring is not yet standard of care everywhere, but it is increasingly used in clinical trials to identify patients at high risk of recurrence who might benefit from additional or intensified treatment.
The ER-Low Gray Zone
Another area of active debate is where HER2-zero tumors sit when the estrogen receptor result is ambiguous. The traditional cutoff for calling a tumor ER-positive varies by country. Swedish guidelines, for instance, define ER-positive as 10% or more of tumor cells staining positive.14The Lancet Regional Health – Europe. Estrogen receptor-low HER2-negative breast cancer as part of triple-negative breast cancer: a population-based nationwide study In the United States, guidelines have historically used a 1% threshold. This means a tumor with, say, 5% ER staining would be classified and treated as TNBC in one country and as hormone receptor-positive in another.
A large Swedish population-based study examined whether ER-low tumors (1–9% staining) that were HER2-negative behaved differently from ER-zero tumors. In an unadjusted analysis, ER-low patients appeared to have slightly better overall survival, but after adjusting for other factors like age, stage, and grade, the difference vanished. Distant disease-free survival was essentially identical between the two groups.15PubMed Central. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study The practical takeaway: ER-low, HER2-negative tumors behave much like classic TNBC and probably deserve the same intensive treatment approach. This is relevant to HER2-zero TNBC specifically, because clinicians sometimes wonder whether faint ER staining in a HER2-zero tumor should change the treatment strategy. The emerging consensus is that it usually should not.
Molecular Features of HER2-Zero TNBC
TNBC is not a single disease. It encompasses a range of tumor types with different genetic profiles, immune characteristics, and metabolic behaviors that happen to share the same three negative biomarkers. TP53 mutations are especially common across TNBC, found in about 75% of cases in one study, which was significantly higher than in HER2-positive breast cancers.16PubMed Central. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy TP53 is a tumor-suppressor gene sometimes called the “guardian of the genome,” and losing it removes a major brake on cell growth and genomic instability.
One question researchers have asked is whether HER2-zero and HER2-low tumors within TNBC differ in their immune microenvironment. A higher density of tumor-infiltrating lymphocytes, or immune cells within the tumor, is generally a good sign in TNBC: it predicts better responses to chemotherapy and better outcomes. However, at least one study found no significant difference in immune cell density or pathologic response rates between HER2-zero and HER2-low TNBC.17Breast Cancer Research. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected? This suggests that whatever drives the prognostic difference between HER2-zero and HER2-low tumors, it is not simply a matter of one group being more immunologically “hot” than the other.
Disparities in Who Gets HER2-Zero TNBC
TNBC overall disproportionately affects certain populations. African American women have a higher prevalence of TNBC than European American women and experience worse clinical outcomes, driven by a combination of biological and non-biological factors.18PubMed Central. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors Biological risk factors include a higher frequency of aggressive molecular subtypes, while non-biological factors include disparities in access to timely screening, diagnosis, and treatment. These disparities are likely amplified in the HER2-zero subgroup, where the narrower range of targeted therapies means that access to clinical trials and emerging drugs becomes even more critical for outcomes.
Because many of the newest treatments for HER2-zero TNBC, like antibody-drug conjugates and immunotherapy combinations, are most available at large academic medical centers or through clinical trials, geography and insurance status can shape who benefits from recent advances. This is an ongoing equity challenge in oncology, and it hits hardest in tumor types like HER2-zero TNBC that depend on cutting-edge therapies to improve historically poor outcomes.
Drug Resistance and What Happens When ADCs Stop Working
Even when targeted therapies work initially, resistance often develops. For antibody-drug conjugates, one common escape route is that the tumor reduces or eliminates the surface protein the drug is designed to grab onto. With sacituzumab govitecan, for instance, a specific mutation in the Trop-2 receptor has been identified in relapsing patients that reduces the drug’s ability to bind effectively.19Oxford Academic. Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies Other resistance mechanisms include the cancer cell pumping the chemotherapy payload out before it can do damage, or changes in the internal processing of the drug once it enters the cell.
For HER2-zero TNBC patients, resistance is a particular concern because there are fewer backup targeted options. When a HER2-low patient’s tumor stops responding to T-DXd, sacituzumab govitecan targeting a different receptor remains an option, and vice versa. A HER2-zero patient already starts without the T-DXd option in most treatment settings, so losing sacituzumab govitecan to resistance narrows the therapeutic window considerably. Researchers are working on next-generation ADCs targeting other surface proteins, combination strategies designed to prevent or delay resistance, and drugs that re-sensitize tumors to ADCs they have become resistant to.
Vaccines and the Research Frontier
Beyond established treatments, some of the most intriguing early-stage research involves cancer vaccines aimed at TNBC. These are therapeutic vaccines, designed to treat existing disease or prevent recurrence rather than prevent cancer from developing in the first place. Several approaches are being explored in preclinical models, including vaccines targeting MUC1, a protein found on the surface of many TNBC cells. In mouse models of TNBC, MUC1-based vaccines have shown the ability to shift the immune environment within tumors: reducing immune-suppressive cell populations and boosting cancer-fighting T cells. Combining these vaccines with immune checkpoint blockers amplified the effect further.20PubMed Central. The search for a TNBC vaccine: the guardian vaccine
This research is still in its early stages, nowhere near clinical use, but the concept addresses a core problem in HER2-zero TNBC: the lack of targetable surface proteins. Vaccines work differently from drugs that bind to a specific receptor. They train the immune system to recognize tumor-associated proteins, potentially providing longer-lasting protection against recurrence. For a cancer subtype defined by the absence of the usual targets, redirecting the immune system toward other vulnerabilities is a logical and promising direction, even if the clinical payoff is years away.
Metabolic Differences as Potential Targets
Another area that may eventually open new doors for HER2-zero TNBC involves the metabolism of the cancer cells themselves. TNBC cells tend to reprogram their energy production and nutrient processing in distinctive ways, relying more heavily on certain metabolic pathways to fuel rapid growth and spread.21PubMed Central. Metabolic reprogramming in triple-negative breast cancer This includes increased dependence on glucose breakdown, altered amino acid usage, and changes in how the cells handle fats. Each of these altered pathways represents a potential point of intervention, and some experimental drugs targeting cancer metabolism are in clinical trials for various solid tumors.
For HER2-zero TNBC specifically, metabolic targeting is attractive because it does not require the tumor to express a specific surface protein. Instead, it exploits internal cellular machinery that differs between cancer cells and normal cells. Whether any of these metabolic strategies will deliver meaningful clinical benefits remains to be seen, but they represent one of several parallel efforts to expand the treatment toolkit for a group of patients who currently have fewer options than almost any other breast cancer subtype.